Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Retatrutide vs Semaglutide

Q: What is the difference between Retatrutide and Semaglutide?

Retatrutide is a GLP-1 compound (Subcutaneous route) - Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. Semaglutide is a GLP-1 compound (Subcutaneous route) - Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects.

Q: Which has a longer half-life, Retatrutide or Semaglutide?

Semaglutide has the longest published plasma half-life (~6.9 days (165 h)), compared with Retatrutide (~6.0 days (144 h)).

Q: How often is each compound dosed in the research literature?

Retatrutide: once weekly at a published dose range of 2–12 mg; Semaglutide: once weekly at a published dose range of 0.25–2.4 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Retatrutide and Semaglutide for research use?

Yes - Retatrutide, Semaglutide are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

GLP1-RC-RT

Retatrutide

Triple receptor agonist

GLP-1R · GIPR · GCGR

GLP1-RC-SM

Semaglutide

GLP-1R agonist

GLP-1R

Key research differences

Retatrutide Semaglutide Receptor profile GLP-1R · GIPR · GCGR GLP-1R Development status Investigational Approved therapeutic molecule Published half-life ~6.0 days (144 h) ~6.9 days (165 h) Research distinction Adds glucagon receptor agonism Selective GLP-1R agonism

Published research parameters

Retatrutide LY3437943 View Retatrutide → Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Receptor profile GLP-1R · GIPR · GCGR GLP-1R Class Triple receptor agonist GLP-1R agonist Plasma half-life ~6.0 days (144 h) ~6.9 days (165 h) Time to Cmax 36 h 24 h Development status Investigational Approved therapeutic molecule Study context Peer-reviewed human PK Regulatory label PK Primary publications Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023) FDA Wegovy USPI — half-life ~1 week (165 h) (2024) Summary Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects.

View published study parameters

Retatrutide LY3437943 View Retatrutide → Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Route in published studies Subcutaneous Subcutaneous Published study interval Once weekly Once weekly Published dose range 2–12 mg 0.25–2.4 mg Published study regimen 2 → 4 → 6 → 8 → 12 mg 0.25 → 0.5 → 1 → 1.7 → 2.4 mg

Source references

Jastreboff AM et al.

New England Journal of Medicine · 2023

Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)

Rosenstock J et al.

The Lancet · 2023

Rosenstock J et al., Lancet 402:529 (titration arms) (2023)

FDA Wegovy USPI — half-life ~1 week (165 h)

FDA prescribing information · 2024

FDA Wegovy USPI — half-life ~1 week (165 h) (2024)

STEP 1 trial — NEJM 384:989 (titration schedule)

New England Journal of Medicine · 2021

STEP 1 trial — NEJM 384:989 (titration schedule) (2021)

Hall S et al.

Clinical Pharmacokinetics · 2018

Hall S et al., Clin Pharmacokinet 57:1571 (Cmax ~24 h SC) (2018)

Frequently asked questions

What is the difference between Retatrutide and Semaglutide?

Which has a longer half-life, Retatrutide or Semaglutide?

How often is each compound dosed in the research literature?

Can you buy Retatrutide and Semaglutide for research use?

Continue researching

Research guides, current certificates and related research for Retatrutide and Semaglutide. Research use only.

Research guide Retatrutide research guide Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for… Read the guide →

Research guide Semaglutide research guide Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a… Read the guide →

Analytical evidence View the Retatrutide COA Current batch purity and identity testing, 2026-07-24. View the COA →

Analytical evidence View the Semaglutide COA Current batch purity and identity testing, 2025-04-30. View the COA →

Compare Compare Retatrutide and Tirzepatide Retatrutide vs Tirzepatide: mechanism, receptor profile and specifications side by side. Compare →

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research